R. Kerbel, Tumor Angiogenesis, New England Journal of Medicine, vol.358, issue.19, pp.2039-2049, 2008.
DOI : 10.1056/NEJMra0706596

J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nature Medicine, vol.326, issue.1, pp.27-31, 1995.
DOI : 10.1038/359845a0

P. Carmeliet and R. Jain, Angiogenesis in cancer and other diseases, pp.249-257, 2000.

G. Taraboletti and B. Margosio, Antiangiogenic and antivascular therapy for cancer, Current Opinion in Pharmacology, vol.1, issue.4, pp.378-384, 2001.
DOI : 10.1016/S1471-4892(01)00065-0

G. Tozer, C. Kanthou, and B. Baguley, Disrupting tumour blood vessels, Nature Reviews Cancer, vol.48, issue.8, pp.423-435, 2005.
DOI : 10.1038/sj.bjc.6690416

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, and J. Hainsworth, Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

F. Kabbinavar, J. Schulz, M. Mccleod, T. Patel, and J. Hamm, Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial, Journal of Clinical Oncology, vol.23, issue.16, pp.3697-3705, 2005.
DOI : 10.1200/JCO.2005.05.112

K. Miller, L. Chap, F. Holmes, M. Cobleigh, and P. Marcom, Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer, Journal of Clinical Oncology, vol.23, issue.4, pp.792-799, 2005.
DOI : 10.1200/JCO.2005.05.098

D. Siemann, D. Chaplin, and M. Horsman, Vascular-targeting therapies for treatment of malignant disease, Cancer, vol.88, issue.12, pp.2491-2499, 2004.
DOI : 10.1002/cncr.20299

D. Siemann, Vascular targeting agents. Horizons in cancer therapeutics: From bench to
DOI : 10.1016/s0360-3016(02)04141-x

URL : http://ufdc.ufl.edu/LS00000881/00112